GlobalData on MSN5d
Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patientsPBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
Zacks.com on MSN5d
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III StudyGSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...
GSK has announced positive headline results of its ongoing global Phase III clinical trial GLISTEN, which is evaluating the use of linerixibat in the treatment of adult patients with cholestatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback